Ventyx Biosciences, Inc. Income Statement
VTYX / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| SG&A Expense | $31.4M | $32.2M | $25.4M | $8.7M | $684.0K |
| R&D Expense | $117.0M | $175.8M | $87.7M | $58.5M | $6.4M |
| Operating Income | -$148.4M | -$208.0M | -$113.1M | -$67.1M | -$7.0M |
| Net Income | -$135.1M | -$193.0M | -$108.4M | -$83.7M | -$28.2M |
| EPS (Basic) | -$1.97 | -$3.30 | -$2.07 | -$6.65 | - |
| EPS (Diluted) | -$1.97 | -$3.30 | -$2.07 | -$6.65 | - |
| Shares Outstanding | 68.5M | 58.5M | 52.5M | 12.8M | 2.0M |